Lung cancer is the one of the most common types of cancer doctors diagnose each year in the U.S. The most common kind of lung cancer is non-small-cell lung cancer (NSCLC). It makes up around 84% ...

The following is a summary of "Prediction of radiosensitivity in non-small cell lung cancer based on computed tomography and tumor genomics: a multiple real-world cohort study," published in the April ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC).

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Common symptoms of non-small cell lung cancer (NSCLC) include frequent coughing that worsens over time, chest pain, and shortness of breath. Non-small cell lung cancer (NSCLC) is the most common ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...